IND clearance de-risks the preclinical-to-clinical transition for LB2501, but the asset is years from commercialization. Monitor initial safety/efficacy data from the China Phase 1 study (NCT07002112) and enrollment progress for the U.S. Phase 1/2 trial as the next catalysts.
Price Chart
Executive Summary
Legend Biotech announced FDA clearance of its IND application for LB2501, a first-in-class dual-targeting (CD19/CD20) in vivo CAR-T therapy for relapsed/refractory B-cell malignancies. This early-stage regulatory milestone supports a planned U.S. Phase 1/2 study but provides no clinical data, making it a modest pipeline catalyst.
Key Facts
- FDA cleared IND for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy.
- LB2501 is the first known dual-targeting in vivo CAR-T to receive FDA IND clearance.
- Planned U.S. Phase 1/2 study will evaluate safety, tolerability, PK, and preliminary efficacy.
- LB2501 is designed as off-the-shelf, single-infusion, without lymphodepleting chemotherapy.
- An ongoing Phase 1 study (NCT07002112) in China is already evaluating LB2501.
- LB2501 is built on Legend's proprietary TaVec lentiviral vector platform.
Financial Impact
No financial figures provided; early-stage pipeline event with no revenue or cost data.
Risk Factors
- In vivo CAR-T is an unproven modality; clinical failure risk is high.
- No clinical data disclosed; all statements are forward-looking.
- Competition from established CD19 CAR-T therapies (e.g., Yescarta, Kymriah) and other in vivo approaches.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006646 |
| Document: f6k_101426.htm | 0001171843-26-006646 |
| Document: 0001171843-26-006646-index-headers.html | 0001171843-26-006646 |
| Document: 0001171843-26-006646-index.html | 0001171843-26-006646 |
| Document: 0001171843-26-006646.txt | 0001171843-26-006646 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $19.80 | awaiting T+20 | — | $20.39 (+2.98%) |
Oct 13, 2026 13d ago | 6-K | $17.88 | awaiting T+20 | — | $20.39 (+14.04%) |
Sep 29, 2026 27d ago | 144 | $18.82 | awaiting T+20 | — | $20.39 (+8.34%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 15, 2026 5w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $20.39 (+15.39%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $20.39 (+10.04%) |
Aug 11, 2026 10w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $20.39 (−6.60%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $20.39 (−5.81%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $20.39 (+5.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers